Effect of leukocyte-reduced platelet-rich plasma on osteoarthritis caused by cranial cruciate ligament rupture: A canine gait analysis model

José M. Vilar¹,²*, Maria E. Manera¹, Angelo Santana¹, Giuseppe Spinella³, Oliver Rodriguez¹, Mónica Rubio⁴, José M. Carrillo⁴, Joaquín Sopena⁴, Miguel Batista¹,²

¹ Departamento de Patología Animal, Facultad de Veterinaria de la Universidad de Las Palmas de Gran Canaria, Trasmontaña S/N, Arucas, Las Palmas, Spain, ² Instituto Universitario de Investigaciones Biomédicas y Sanitarias, Universidad de Las Palmas de Gran Canaria, Juan de Quesada 30, Las Palmas de Gran Canaria, Las Palmas, Spain, ³ Dipartimento di Science Mediche Veterinarie, Facoltà di Veterinaria de la Università di Bologna, Via Tolara di sopra 50, Ozzano, Bologna, Italy, ⁴ Departamento de Medicina y Cirugía Animal, Universidad CEU Cardenal Herrera, C/Tirant lo Blanc, 7, Alfara del Patriarca, Valencia, Spain

* jose.vilar@ulpgc.es

Abstract

The goal of this study was to objectively assess the effect of a platelet-rich plasma (PRP) derivate in English bulldogs with stifle degenerative joint disease secondary to cranial cruciate ligament rupture (CCLR). We used a force platform and affixed electrogoniometers to measure peak vertical force (PVF), vertical impulse (VI), stance time (ST), and angular range of motion (AROM), from 12 lame client-owned English bulldogs with post-CCLR stifle joint abnormalities. The 12 affected subjects were treated with 4 intra-articular injections of PRP, at 30-day intervals. Ten untreated, sound English bulldogs were used as a reference group. Clinical outcomes were evaluated using a linear mixed effects model. Mean values of PVF, VI, ST, and AROM were improved within the first 3 months post-treatment in the CCLR group, with mean measured changes increasing to maximum 4.56% body weight gain, 1.5% body weight/second, 0.07 seconds, and 6.18 degrees, respectively. The effects declined progressively after the treatment interval, ending at nearly initial levels after 6 months. This study demonstrates that dogs with CCLR treated with intra-articular PRP had improved PVF, VI, ST, and AROM over time; the duration of effect was waning by the end of the post-treatment period.

Introduction

Cranial cruciate ligament rupture (CCLR) is one of the most significant stifle injuries in domestic dogs, and is a common cause of chronic lameness [1]. A CCLR results in joint instability leading to osteoarthritis (OA) and degenerative joint disease [2–6]. Progressive joint degeneration produces changes in catabolic and anabolic activity of chondrocytes [7], impairing functional capability, producing pain, limiting flexibility and motion and lowering quality of life [8].
Various surgical techniques have been advocated to treat CCLR, including extracapsular stabilization, tibial plateau-leveling osteotomy, and tibial tuberosity advancement [9]. Conservative management includes weight loss [10], omega-3 fatty acid supplementation [11] and use of NSAID drugs [12].

Recently, innovative treatments for modulating joint pain have been introduced, including chemical precursors, mesenchymal stem cell therapy, and growth factors obtained from platelet-rich plasma (PRP). These treatments can be used alone or in combinations [6,13]. Platelets have high concentration of growth factors, making PRP an appealing therapeutic alternative. The platelet growth factors could favorably influence need for analgesia, soft tissue healing, regulation of anti-inflammatory signals [14], and vascularizing and innervating of autografts [15].

Based on experimental results, PRP alone or as a co-therapy with surgical repair, can reduce progression of OA, without undesirable side effects [16,17]. It can be difficult to compare therapeutic studies directly because of differing assessment criteria, clinical measures (ie, OA classification systems), inclusion and exclusion criteria, varying aetiologies or the many possible intrinsic patient factors. Thus, objective measures of level and duration of efficacy represent significant advancements in experimental methods [18].

Force platform gait analysis is an objective, quantitative, non-invasive, and reliable method to characterize ground reaction forces during locomotion [19,20]. This kinetic methodology has been used to characterize gait in dogs after CCLR [1], but not for objective assessment of the effect of PRP in dogs with stifle OA that is secondary to naturally-occurring CCLR. On the other hand, electrogoniometers have been used to measure dog joint metrics such as range of angular movement (AROM) [21].

We hypothesize that PRP therapy has beneficial effects in dogs with CCLR, but that this effect may be limited in terms of time. To test this hypothesis, we used force platform and electrogoniometric gait analysis to determine efficacy and duration of effect of PRP therapy in English bulldogs with unilateral CCLR. An additional goal was to estimate an initial dosing regimen for further research.

Materials and methods

Dogs

All procedures were approved by the Ethics Committee of the Research Institute in Biomedical and Health Sciences of the University of Las Palmas de Gran Canaria (Spain), in compliance with national (Royal Decree 1201/2005) and European Union regulations (European Directive 86/609/CE) for projects using animals for research. A total of 22 adult, client-owned English bulldogs were included in the study. Ten of them served as clinically normal, unaffected, untreated control group. General inclusion criteria consisted of body weight between 18–27 kg and age between 1.5–6 years.

CCLR group. To qualify for our study design, post-CCLR dogs (n = 12) would be overtly lame on the ipsilateral injury side and would lack evidence of concurrent systemic or other orthopaedic disease. Medical screening included hematology, urinalysis, serum biochemical profiles, and no medication given over the preceding 4 weeks. All dogs were evaluated for articular effusion and for tibial compression and cranial drawer tests to assess the integrity of the cranial cruciate ligament.

Bilateral stifle radiographs were made under tibial compression with each dog in ipsilateral recumbency. CCLR was confirmed by observing cranial displacement of the proximal end of the tibia with respect to the femoral condyles, and any radiographic signs that were consistent with osteoarthritis. The radiological and physical evaluations also were needed to confirm that the stifle joint disease was unilateral.
Control group. The dogs selected for the Control group (n = 10) would not have current or previous history of orthopaedic or neurologic disease, nor persistent injury or systemic disease, confirmed by general physical examination, orthopedic evaluation, and radiology. None of the control dogs were forced to perform physical activities. Dog owners signed an informed consent form that allowed their dogs to participate in the study.

Preparation and administration of PRP
Prior to platelet collection and activation, blood platelet and leukocyte counts were obtained. Whole blood (10 mL) was extracted aseptically from a cephalic vein and collected in two 5-mL centrifuge tubes, each containing 1.0 mL sodium citrate (2.5% solution) as anticoagulant. The tubes were centrifuged (Centronic JP selecta, model 7000015, Barcelona, Spain) for 10 min at 210 x g. Only the lower one-third of the yielded plasma (adjacent to the buffy coat) was activated with 5% of its volume, using 10% calcium chloride. The resultant ~2 mL solution was injected aseptically into the affected stifle joint through the conventional arthrocentesis site [22]. The appearance of joint fluid confirmed proper needle placement. A total of four doses were administered on days 0, 7, 14 and 21. After each inoculation, exercise was restricted for 2 days by confining to a walk at a maximum of 30 minutes/day on a leash. For the remaining days, dogs could walk on a leash a maximum of three times daily for 30 minutes, until the end of the experiment. No dogs were engaged in strenuous activity during the study.

Gait analysis
Kinetic analysis was performed using a single platform mounted in the centre of, and level with, a 7-m runway covered by a rubber mat. The mat weight was eliminated by setting it to “0 force” with the tare button, after the platform was covered. Dogs were leash-guided at a walk over the force platform, always by the same handler. Walk velocity was measured using a motion sensor (Pasco, Roseville, California, USA) positioned 1-m from the platform.

Five valid trials were obtained for each dog, at a sampling frequency of 250 Hz. A trial was considered valid when the limb fully contacted the force platform and the dog walked next to the handler without pulling on the leash. The trial was discarded if the dog was distracted during the measurement, if the limb struck the edge of the force plate, or if any portion of the contralateral paw hit the force plate. A member of the research team (OR) evaluated the trial to confirm which limb touched the centre of the force platform. The platform was interfaced with a dedicated computer using DataStudio (Pasco, Roseville, California, USA), a software specially designed for acquisition, numerical conversion, and storage of data. A team member (JMV) recorded data from affected limbs at Day D0, D30, D90 and D180 after the first administration of PRP. Data from sound dogs were obtained at the same intervals; the Peak Vertical Forces (PVF) and Vertical Impulse (VI) values were normalized to body weight (as %) to characterize possible improvement of lameness during treatment with PRP. The Stance Time (ST) value was acquired directly from DataStudio.

Immediately after the force platform examination, electrogoniometry was performed using an electrogoniometer (Pasco) placed over the lateral collateral ligament of the stifle and affixed with adhesive plasters by an experienced researcher (OR). After the dogs were observed to be comfortable with the device, five consecutive steps were recorded. Electrogoniograms were obtained with the same software used to obtain the AROM.

Statistical analysis
The purpose of the experiment was to determine if systematic differences exist in PVF, VI, ST and AROM in dogs with CCLR under PRP treatment given at four fixed moments in time: D0, D7, D14, and D21.
D30, D90, D180. For this reason, a linear mixed effects model was used with the experimental factor (time) as a fixed effect and the blocking factor (dog) as a random effect. The model is as follows:

\[ y_{ijk} = \mu_j + b_i + b_{ij} + \mu_{ijk}; \ i = 1, \ldots, 5; \ j = 1, \ldots, 4; \ k = 1, \ldots, n \]

\[ b_i \approx N(0, \sigma_b); \ b_{ij} \approx N(0, \sigma); \ \mu_{ijk} \approx N(0, \sigma) \]

where \( y_{ijk} \) is the \( k \)-th measure of PVF, VI, ST and AROM, for the dog \((i = 1 \ldots 5)\) on day \( j = 1 \) (0), 2 (30), 3 (90), and 4 (180); \( \mu_j \) is the (fixed) effect of time \( j \). This parameter represents PVF, VI, ST, and AROM in the CCLR group, at the \( j \)-th observation. For \( b_i \), the (random) effect of dog, values are anticipated to be normally distributed, with mean 0 and standard deviation \( \sigma_b \). Thus, \( \sigma_b \) is the variability in the response due to the dogs; \( \sigma \) is the interaction effect between dog and time of observation (\( j \)). This term allows for the possibility that some dogs could improve at the same time period as others worsen. \( \mu_{ijk} \) is the residual in the measure \( ijk \). This variable also is assumed to be normally distributed with mean 0 and standard deviation \( \sigma \). \( \eta_{ij} \) is the number of replicates of the PVF, VI, ST and AROM, measures on the dog at each time interval.

Metrics in this model were estimated using the nlme package in R statistical software (https://www.r-project.org/). For comparing fixed effects, the multiple comparison test of Tukey was applied. For assessing the validity of the model, a Shapiro-Wilk test was applied for testing normality of the residuals, and a Levene’s test was done for testing homoscedasticity. Ninety-five percent confidence intervals for differences between CCLR and Control groups at serial intervals also were computed. Statistical power analysis was calculated with Glimmpse® (http://glimmpse.samplesizeshop.org/#/).

**Results**

The CCLR group contained 4 female and 8 male dogs, and the Control group consisted of 4 female and 6 male dogs. The mean (± SD) body weight of enrolled dogs was 22.83 ± 2.62 kg in the CCLR group and 23 ± 3.01 kg in the Control group (\( P = 0.30 \)). Mean age was 3.6 ± 1.14 in the CCLR group and 4 ± 1.22 in the Control group (\( P = 0.54 \)).

The mean value for walking velocity of both sound (Control) and CCLR group dogs was 0.7 ± 0.2 m/s (\( P = 0.12 \)). Mean values (± SD) for PVF, VI, ST and AROM, in both CCLR and Control groups are summarized in Table 1. Data were distributed normally and were homoscedastic.

The PRP obtained under this protocol revealed mean platelet count of 1013 ± 431 x 10^3 cells/μL (≈ 336% baseline count) and mean leukocyte count of 0.1 ± 0.1 x 10^3 cells/μL (Table 2).

**Analysis of PVF**

Comparing with D0, mean PVF in the CCLR group increased by 4.56% at D30 (\( P < 0.0001 \)); 3.34% increase was found at D90 (\( P < 0.0001 \)); and 0.97% increase at D180 (\( P = 0.0077 \)). Compared with the Control group, lower PVF was found at D0 (4.96%) (\( P < 0.0001 \)) and D180 (3.57%) (\( P < 0.0001 \)) (Fig 1).

**Analysis of VI**

VI was increased 1.5% at D30 (\( P < 0.0001 \)), 0.9% at D90 (\( P < 0.0001 \)), and 0.4% at D180, all as compared with day 0 (\( P = 0.003 \)).
Comparison of the CCLR and Control groups revealed significant differences at D0 (1.13% less) (P < 0.0001), and at D180 (0.63% less) (Fig 2) (P < 0.0001).

Analysis of ST
In the CCLR group, with respect to D0, ST increased in 0.07s, 0.04s, and 0.03s at D30 (P = 0), D90 (P = 0), and D180 (P = 0.004224), respectively.

Compared with Controls, affected dogs’ ST was 0.05s less at D0 (P = 9.1–9). At D30, the difference was not significant. At D90 and D180, ST again was lower (0.044s and 0.019s, respectively) (P = 0.039) (Fig 3).

Analysis of AROM
Analysis of variance revealed that at D30, AROM increased by 5.68 degrees, compared with D0 (P < 0.0001). AROM increased to 6.18 degrees at D90 (P < 0.0001).

Compared with the Control group, CCLR dogs had AROM 6.48 degrees less at D0 (P < 0.0001); at D30 and D90, no differences were found. However, at D180, AROM decreased by 6.17 degrees (P < 0.0001) (Fig 4).

Our sample size of 12 dogs provided a statistical power of 83% for the detection of differences of 0.5% of each parameter among individuals.

Discussion
We assessed PVF, VI, ST, and AROM changes in lame English bulldogs with unilateral CCLR treated with PRP. We used a force platform and electrogoniometry. The data provided support our hypothesis that PRP therapy is effective for OA secondary to CCLR, although the effect is temporary.

To our knowledge, this is the first study that provides objective data regarding PRP treatment outcomes in dogs with sequelae to naturally occurring CCLR.

Table 1. Mean and standard deviation (mean ± SD) of force plate analysis data (n = 22) for the lame leg in CCLR group and Control group. Data are shown in percent of dog weight (PVF, VI), in seconds (ST), and degrees (AROM).

| Parameter | Day after treatment | SWT | LT |
|-----------|---------------------|-----|-----|
|           | D0                  | D30 | D90 | D180 |       |     |
| PVF       |                     |     |     |      |       |     |
| CCLR      | 35.13 ± 1.08#       | 39.69 ± 1.10" | 38.47 ± 1.31" | 36.10 ± 0.78#" | 0.09 | 0.7 |
| Control   | 40.09 ± 0.84        | 39.34 ± 0.66 | 39.32 ± 0.76 | 39.37 ± 0.51 |     |     |
| VI        |                     |     |     |      |       |     |
| CCLR      | 10.79 ± 0.61#       | 13.28 ± 0.66’ | 11.69 ± 0.55’ | 11.19 ± 0.62#’ | 0.20 | 0.40 |
| Control   | 11.90 ± 0.60        | 11.89 ± 0.65 | 11.95 ± 0.58 | 11.82 ± 0.46 |     |     |
| ST        |                     |     |     |      |       |     |
| CCLR      | 0.38 ± 0.03*        | 0.45 ± 0.05’ | 0.43 ± 0.03* | 0.40 ± 0.03* | 0.37 | 0.60 |
| Control   | 0.43 ± 0.03         | 0.44 ± 0.04 | 0.45 ± 0.03 | 0.43 ± 0.03 |     |     |
| AROM      |                     |     |     |      |       |     |
| CCLR      | 25.10 ± 3.15*       | 30.78 ± 1.96’ | 31.25 ± 1.56’ | 25.49 ± 3.67#’ | 0.82 | 0.45 |
| Control   | 31.58 ± 0.61        | 31.51 ± 0.62 | 31.62 ± 0.69 | 31.67 ± 0.58 |     |     |

PVF = peak vertical force, CCLR = cranial cruciate ligament rupture group, VI = vertical impulse, ST = stance time, AROM = angular range of motion
# significant difference (p<0.05) between study and Control group.
* significant difference (p<0.05) in the study group between checking periods and D0, SWT Shapiro-Wilk test value, LT Levene test value.

https://doi.org/10.1371/journal.pone.0194752.t001
PRP therapy was demonstrated to have a positive effect on limb function. Specifically, we observed improved locomotion, associated with reducing both lameness and gait disability, allowing the dogs to support more weight on their hind limbs and reach greater AROM. Important factors that make it difficult to compare results among studies are the diverse methods and devices used to evaluate pain and lameness. In this sense, PRP joint therapy requires more investigation, focused specially on assessing its efficacy across therapies, using objective, and reliable assessment tools.

When kinetic evaluation is performed, some authors state that the force plate gait analysis yields large variation in normal ground reaction forces, preventing meaningful direct comparison of data among different dogs or among dog groups having differing conformation (breed) [23]. Under this premise, comparative studies necessarily require rescaling, harmonization, or normalization of data. In our study, we chose all dogs of the same breed to provide more standardized data sets.

Regarding ST, a kinematic parameter, one report indicated that a group of dogs treated with NSAIDs experienced decrease in ST when they were able to improve their performance [24]. However, other reports indicate that ST remained unchanged or increased as limb function improved [25,26]. If pain is suppressed effectively, we suggest that ST should improve after effective treatment.
Fig 1. PVF values in CCLR group at the 6-month follow-up period after treatment with platelet-rich plasma. Data from Control group also are shown.

https://doi.org/10.1371/journal.pone.0194752.g001

Fig 2. VI values in CCLR group at the 6-month follow-up period after treatment with platelet-rich plasma. Data from Control group also are shown.

https://doi.org/10.1371/journal.pone.0194752.g002
Fig 3. ST values in CCLR group at the 6-month follow-up period after treatment with platelet-rich plasma. Data from Control group also are shown.

https://doi.org/10.1371/journal.pone.0194752.g003

Fig 4. AROM values in CCLR group at the 6-month follow-up period after treatment with platelet-rich plasma. Data from Control group also are shown.

https://doi.org/10.1371/journal.pone.0194752.g004
Recent reports have shown that the presence of leukocytes in PRP preparations may be detrimental to healing, due to their involvement in the inflammatory response [27] causing loss of pain relief efficacy [28]. We avoided this complication, because our PRP was prepared with nearly complete absence of leukocytes.

Concerning actual administration, there is no consensus at this time about a standard regimen. Thus, PRP treatment for OA can vary from one to a series of nine injections [29–33]. Under this range of treatment protocols, we decide to apply a mid-level of four injections at 7-day interval.

A follow-up evaluation of 6 months could be considered as a minimum standard for testing the outcome of a medical or surgical treatment. In our study, this time was sufficient to recognize significant improvement during the first months after treatment, and also to establish that lame dogs eventually returned nearly to their initial status. The duration of the effect that we noted is consistent with previous reports [34,35]. Based on our results and taking into account that improvement by surgical means can extend relief for more than 2 years [29], PRP therapy may become an alternative resource for those instances wherein affected dogs cannot undergo surgery because of anaesthetic risk or when dog owners cannot afford surgical costs. Other commercially available PRP derivates (PRGF-Endoret®, Orthokine®) have been associated with better effect and/or longer duration, but objectively-generated data remain to be collected, as is the case also with injections of hyaluronic acid or NSAIDs.

Our study has some limitations. First, the number of available dogs was relatively small. Small sample sizes can associate with low statistical power, and previous reports have established that dog conformation and size can affect kinetic measures [23]. Therefore, we decided to prioritize data homogeneity (diminishing the inter-subject variability) by using dogs from the same breed within defined weights and ages. We thus noted that variation of only 0.5% in PVF could be detected with a statistical power of 83%.

Second, although both hind limbs were recorded, we provide only data from the affected limbs for comparison with control dogs. Based on previous reports, force redistribution to contralateral limbs and even to forelimbs (in hind limb lameness) could call this choice into question [36].

Third, our study design included sound dogs as controls when, typically, a Control group would have included untreated affected dogs. However, painful untreated or placebo-treated dogs in a positive Control group could worsen, rendering these dogs unable to provide fixed reference data. Additionally, ethical concerns arise when affected, untreated controls are part of biomedical experimental designs. In accordance with other authors using similar study designs [23], data from sound dogs were provided as an “ideal status” disease-free Control group.

Conclusion

Force platform and electrogoniometric gait analysis established quantitatively that PRP therapy could be useful for treatment of chronic lameness in post-CCLR dogs. Our data indicate efficacy over a period of 3–6 months, without side effects. Maintaining efficacy for durations longer than 3–6 months requires further research.

Supporting information

S1 File. Datasets.
(CSV)
Acknowledgments

This work was supported technically by the Fundación García-Cugat and the Veterinary Clinic Hospital of the Universidad de Las Palmas de Gran Canaria. Technical editing was provided by Amanda K Hand, and Tizol S.

Author Contributions

Conceptualization: José M. Vilar, Giuseppe Spinella, Mónica Rubio, José M. Carrillo, Joaquín Sopena, Miguel Batista.

Data curation: Angelo Santana, Oliver Rodriguez.

Investigation: José M. Vilar, María E. Manera, Giuseppe Spinella, Oliver Rodriguez, Mónica Rubio, Joaquín Sopena.

Resources: Mónica Rubio, José M. Carrillo, Miguel Batista.

Software: Angelo Santana.

Validation: Angelo Santana, José M. Carrillo.

Visualization: Joaquín Sopena.

Writing – original draft: José M. Vilar, María E. Manera.

Writing – review & editing: Miguel Batista.

References

1. Souza AN, Tatarunas AC, Matera JM. Evaluation of vertical forces in the pads of Pitbulls with cranial cruciate ligament rupture. BMC Vet Res. 2014; 10:51. https://doi.org/10.1186/1746-6148-10-51 PMID: 24581287

2. Comerford EJ, Smith K, Hayashi K. Update on the aetiopathogenesis of canine cranial cruciate ligament disease. Vet Comp Orthop Traumatol. 2011; 24:91–98. https://doi.org/10.3415/VCOT-10-04-0055 PMID: 21243176

3. Johnson KA. Special issue on canine cruciate ligament disease. Vet Comp Orthop Traumatol. 2011; 24:3–4.

4. Beraud R, Moreau M, Lussier B. Effect of exercise on kinetic gait analysis of dogs afflicated by osteoarthritis. Vet Comp Orthop Traumatol. 2010; 23:87–92. https://doi.org/10.3415/VCO T-09-06-0068 PMID: 20151081

5. Innes JF, Bacon D, Lynch C, Pollard A. Long-term outcome of surgery for dogs with cranial cruciate ligament deficiency. Vet Rec. 2000; 147:325–328. PMID: 11058021

6. Moreau M, Riauland P, Pelletier JP, Martel-Pelletier J, Lajeunesse D, Boileau C, Caron J, Frank D, Lussier B, del Castillo JR, Beauchamp G, Gauvin D, Bertaim T, Thibaud D, Troncy E. Tildurone treatment improves structural changes and symptoms of osteoarthritis in the canine anterior cruciate ligament model. Arthritis Res Ther. 2011; 13:98.

7. Rayegani SM, Raeissadat SA, Taheri MS, Babae M, Bahrami MH, Eliaspour D, Ghorbani E. Does intra articular platelet rich plasma injection improve function, pain and quality of life in patients with osteoarthritis of the knee? A randomized clinical trial. Orthop Rev. 2014; 6:5405.

8. Zhu Y, Yuan M, Meng HY, Wang AY, Guo QY, Wang Y, Peng J. Basic science and clinical application of platelet rich plasma for cartilage defects and osteoarthritis: a review. Osteoarthritis Cartilage 2013; 21:1627–1637. https://doi.org/10.1016/j.joca.2013.07.017 PMID: 23933379

9. David FH, Grierson J, Lamb CR. Reducing susceptibility artefacts in magnetic resonance images of the canine stifle following surgery for cranial cruciate ligament deficiency. Vet Comp Orthop Traumatol. 2012; 25:488–497. https://doi.org/10.3415/VCO T-12-03-0031 PMID: 22836300

10. Grierson J, Asher L, Grainger K. An investigation into risk factors for bilateral canine cruciate ligament rupture. Vet Comp Orthop Traumatol. 2011; 24:192–196. https://doi.org/10.3415/VCO T-10-03-0030 PMID: 21327290
Gait analysis of the effect of PRP in dogs with CCLR

11. Hansen RA, Harris MA, Pluhar GE, Motta T, Brevard S, Ogilvie GK, Fettman MJ, Allen KG. Fish oil decreases matrix metalloproteinases in knee synovia of dogs with inflammatory joint disease. J Nutr Biochem. 2008; 19:101–108. https://doi.org/10.1016/j.jnutbio.2007.01.008 PMID: 17531456

12. Vilar JM, Morales M, Santana A, Batista M, Miro F, Spinella G. Long-term valuation of oral mavacoxib in osteoarthritic dogs using force platform analysis. Pak Vet J. 2013; 33: 229–233.

13. Vilar JM, Morales M, Santana A, Spinella G, Rubio M, Cuervo B, Cugat R, Carrillo JM. Controlled, blinded force platform analysis of the effect of intraarticular injection of autologous adipose-derived mesenchymal stem cells associated to PRGF-Endoret in osteoarthritic dogs. BMC Vet Res. 2013; 9:131. https://doi.org/10.1186/1746-6148-9-131 PMID: 23819757

14. Raaeisadat SA, Rayegani SM, Hassanabadi H, Rahimi R, Sedighipour L, Rostami K. Is platelet-rich plasma superior to whole blood in the management of chronic tennis elbow: one year randomized clinical trial. BMC Sports Sci Med. Rehabil. 2014; 6:12. https://doi.org/10.1186/2052-1847-6-12 PMID: 24635909

15. Xiaoxing X, Song Z, Hua W, Guoming X, Yaohua H, Jinzhong Z. Platelet-rich plasma enhances autograft revascularization and reinnervation in a dog model of anterior cruciate ligament reconstruction. J Surg Res. 2013; 183:214–222. https://doi.org/10.1016/j.jss.2013.01.020 PMID: 23472861

16. Silva RF, Carmona JU, Rezende CM. Intra-articular injections of autologous platelet concentrates in dogs with surgical repair of cranial cruciate ligament rupture: a pilot study. Vet Comp Orthop Traumatol. 2013; 26:285–290. https://doi.org/10.3415/VCOT-12-06-0075 PMID: 23612687

17. Fahie MA, Ortolano GA, Guercio V, Schaffer JA, Johnston G, Au J, Hetlich BA, Phillips T, Allen MJ, Bertone AL. A randomized controlled trial of the efficacy of autologous platelet therapy for the treatment of osteoarthritis in dogs. J Am Vet Med Assoc. 2013; 243:1291–1297 https://doi.org/10.2460/javma.243.9.1291 PMID: 24134578

18. Rodriguez-Merchan C. Intraarticular injections of platelet-rich plasma (PRP) in the management of knee osteoarthritis. Arch Bone Joint Surg. 2013; 1:5–8. PMID: 25207275

19. Anderson MA, Mann FA. Force plate analysis: A noninvasive tool for gait evaluation. Compend Contin Educ Pract Vet. 1994; 16:857–867.

20. Raglety CA, Griffon DJ, Klump LM, Hsiao-Weckslar ET. Pelvic limb kinetic and kinematic analysis in Labrador retrievers predisposed or at a low risk for cranial cruciate ligament disease. Vet Surg. 2012; 41:973–982. https://doi.org/10.1111/j.1532-950X.2012.01042.x PMID: 23199624

21. Colin A, Maître P, Lequang T, Thiebaut J, Viguier E. Dog limbs electrogoniometric study at walking gait. Comput Methods Biomech Biomed Engin. 2007;Suppl 1:107–108.

22. Pierrat D L, Flo GL, DeCamp CE. In Pierrat D L, Flo GL, DeCamp CE, Editors. The Stifle Joint, handbook of Small Animal Orthopedics and Fracture Repair, St. Louis: Elsevier Inc; 2006, pp. 562–632.

23. Molis SH, Hyytialainen HK, Hielm-Björkman AK, Laitinen-Vapaavouri OM. Long-term functional outcome after surgical repair of cranial cruciate ligament disease in dogs. BMC Vet Res. 2014; 10:266. https://doi.org/10.1186/s12917-014-0266-8 PMID: 25407015

24. Moreau M, Lussier B, Doucet M, Vincent G, Martel-Pelletier J, Pelletier JP: Efficacy of licofelone in dogs dysplasia. Am J Vet Res. 1996; 57:966–971. PMID: 8807004

25. Bennett RL, DeCamp CE, Flo GL, Hauptman JG, Stajich M. Kinematic gait analysis in dogs with hip dysplasia. Am J Vet Res. 1996; 57:966–971. PMID: 8807004

26. DeCamp CE, Riggs CM, Olivier NB, Hauptman JG, Hottinger HA, Soutas-Little RW. Kinematic evaluation of gait in dogs with cranial cruciate ligament rupture. Am J Vet Res. 1996; 57:120–126. PMID: 8720250

27. González JC, López C, Alvarez ME, Pérez JE, Carmona JU. Autologous leukocyte-reduced platelet-rich plasma therapy for Achilles tendinopathy induced by collagenase in a rabbit model. Sci Rep. 2016 Jan 19; 6:19623. https://doi.org/10.1038/srep19623 PMID: 26718753

28. Yoshida M, Funasaki H, Marumo K Efficacy of autologous leukocyte-reduced platelet-rich plasma therapy for patellar tendinopathy in a rat treadmill model. Muscles Ligaments Tendons J. 2016; 6:205–215. https://doi.org/10.11138/mltj/2016.6.2.205 PMID: 27900294

29. Moraes VY, Lenza M, Tamaoki MJ, Faloppa F, Belloti JC. Platelet-rich therapies for musculoskeletal soft tissue injuries. Cochrane Database Syst Rev. 2014; 4;CD010071.

30. Sánchez M, Anitura E, Azofra J, Aguirre JJ, Andia I. Intra-articular injection of an autologous preparation rich in growth factors for the treatment of knee OA: a retrospective cohort study. Clin Exp Rheumatol. 2008; 26:910–913 PMID: 19032827

31. Franklin SP, Garner BC, Cook JL. Characteristics of canine platelet-rich plasma prepared with five commercially available systems. Am J Vet Res. 2015; 76:822–827. https://doi.org/10.2460/ajvr.76.9.822 PMID: 26309111
32. Cook JL, Smith PA, Bozynski CC, Kuroki K, Cook CR, Stoker AM, Pfeiffer FM. Multiple injections of leukoreduced platelet rich plasma reduce pain and functional impairment in a canine model of ACL and meniscal deficiency. Orthop Res. 2016; 34:607–615.

33. Hart R, Safi A, Komzák M, Jajtner P, Puskeiler M, Hartová P. Platelet-rich plasma in patients with tibiofemoral cartilage degeneration. Arch Orthop Trauma Surg. 2013; 133:1295–301. https://doi.org/10.1007/s00402-013-1782-x PMID: 23736793

34. Kon E, Buda R, Filardo G, Di Martino A, Timoncini A, Cenacchi A, Fornasier PM, Giannini S, Marcacci M. Platelet-rich plasma: intraarticular knee injections produced favorable results on degenerative cartilage lesions. Knee Surg Sports Traumatol Arthrosc. 2010; 18:472–479. https://doi.org/10.1007/s00167-009-0940-8 PMID: 19838676

35. Filardo G, Kon E, Buda R, Timoncini A, Di Martino A, Cenacchi A, Fornasier PM, Giannini S, Marcacci M. Platelet-rich plasma intra-articular knee injections for the treatment of degenerative cartilage lesions and osteoarthritis. Knee Surg Sports Traumatol Arthrosc. 2011; 19:528–535. https://doi.org/10.1007/s00167-010-1238-6 PMID: 20740273

36. Rumph PF, Kincaid SA, Visco DM, Baird DK, Kammermann JR, West MS: Redistribution of vertical ground reaction force in dogs with experimentally induced chronic hindlimb lameness. Vet Surg. 1995, 24:384–389. PMID: 8585145